Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant

NCT01481272 is registered in ClinicalTrials.gov with Polish Lymphoma Research Group as lead sponsor.

NCT NCT01481272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01481272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial on Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients Progressing or Relapsed After Prior R-CHOP Treatment Not Suitable for Autologous Stem Cell Transplant
Lead sponsor
Polish Lymphoma Research Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2018
Enrollment
77 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma